18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy

Heather A. Jacene, Ross Filice, Wayne Kasecamp, Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

We retrospectively evaluated 18F-FDG PET/CT for monitoring the response of non-Hodgkin's lymphoma to radioimmunotherapy. Methods: A total of 33 clinical patients received 131I-tositumomab (n = 23) or 90Y-ibritumomab tiuxetan (n = 10) and underwent 18F-FDG PET/CT scans before radioimmunotherapy and at 12 wk after radioimmunotherapy. A third scan was performed on 13 patients at 24 wk after radioimmunotherapy, 12 of whom did not receive interval therapy. Tumor metabolic activity was assessed before and after radioimmunotherapy visually and quantitatively by lean maximum standardized uptake value (SUVlean max). Response was assessed by the International Workshop Criteria (IWC) and Revised IWC, which includes 18F-FDG PET (IWC-PET). Results: Mean SUVlean max decreased from baseline in 244 target lesions 12 wk after radioimmunotherapy (from 6.51 ± 4.05 to 3.94 ± 4.41; P <0.01), regardless of response at 12 wk after radioimmunotherapy (P ≤ 0.02). After radioimmunotherapy, SUV lean max was lower for responders than for nonresponders (P ≤ 0.01). Median percentage change in SUVlean max of target lesions per patient was -51% (-95% to 97%). No significant difference in decline in SUV lean max between patients who received 131I-tositumomab and those who received 90Y-ibritumomab tiuxetan was demonstrated (-31% ± 51% vs. -47% ± 46%; P = 0.38). Patients with greater than a 52% decline in SUVlean max tended toward longer survival (P = 0.09) than those with lesser declines. The 12-wk overall response rate to radioimmunotherapy based on IWC was 42% (14/33); complete response rate was 15% (5/33). Eleven of 12 patients with progression at 12 wk had new disease sites, and in 4 patients, new disease sites were the only sites of progression. Of 108 lesions evaluated at 12 and 24 wk after radioimmunotherapy, 49 resolved at 12 wk and remained resolved at 24 wk, 17 gradually declined in SUV over 24 wk, and 37 initially decreased at 12 wk but increased at 24 wk. PET showed disease progression at 24 wk in 10 of 13 patients; 7 patients had new lesions and 1 was reclassified from partial response to complete response. Conclusion: In non-Hodgkin's lymphoma, 18F-FDG uptake in tumors typically drops significantly after radioimmunotherapy. A continued decline in tumor SUV lean max between 12 and 24 wk without additional therapy can occur, suggesting a need for delayed-response assessment. In patients who progress after radioimmunotherapy, new sites of disease commonly develop, rather than recurrence or progression at previous disease sites. Large declines in 18F-FDG uptake tend to be seen in those with the longest progression-free survival.

Original languageEnglish (US)
Pages (from-to)8-17
Number of pages10
JournalJournal of Nuclear Medicine
Volume50
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Radioimmunotherapy
Fluorodeoxyglucose F18
Lymphoma
Education
Non-Hodgkin's Lymphoma
Neoplasms
Disease-Free Survival
Disease Progression

Keywords

  • I- tositumomab
  • F-FDG PET
  • Y-ibritumomab tiuxetan
  • Bexxar
  • Lymphoma
  • Radioimmunotherapy
  • Zevalin

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. / Jacene, Heather A.; Filice, Ross; Kasecamp, Wayne; Wahl, Richard L.

In: Journal of Nuclear Medicine, Vol. 50, No. 1, 01.01.2009, p. 8-17.

Research output: Contribution to journalArticle

Jacene, Heather A. ; Filice, Ross ; Kasecamp, Wayne ; Wahl, Richard L. / 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. In: Journal of Nuclear Medicine. 2009 ; Vol. 50, No. 1. pp. 8-17.
@article{2ad60c4eae0a4c80be1abb0145715c4c,
title = "18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy",
abstract = "We retrospectively evaluated 18F-FDG PET/CT for monitoring the response of non-Hodgkin's lymphoma to radioimmunotherapy. Methods: A total of 33 clinical patients received 131I-tositumomab (n = 23) or 90Y-ibritumomab tiuxetan (n = 10) and underwent 18F-FDG PET/CT scans before radioimmunotherapy and at 12 wk after radioimmunotherapy. A third scan was performed on 13 patients at 24 wk after radioimmunotherapy, 12 of whom did not receive interval therapy. Tumor metabolic activity was assessed before and after radioimmunotherapy visually and quantitatively by lean maximum standardized uptake value (SUVlean max). Response was assessed by the International Workshop Criteria (IWC) and Revised IWC, which includes 18F-FDG PET (IWC-PET). Results: Mean SUVlean max decreased from baseline in 244 target lesions 12 wk after radioimmunotherapy (from 6.51 ± 4.05 to 3.94 ± 4.41; P <0.01), regardless of response at 12 wk after radioimmunotherapy (P ≤ 0.02). After radioimmunotherapy, SUV lean max was lower for responders than for nonresponders (P ≤ 0.01). Median percentage change in SUVlean max of target lesions per patient was -51{\%} (-95{\%} to 97{\%}). No significant difference in decline in SUV lean max between patients who received 131I-tositumomab and those who received 90Y-ibritumomab tiuxetan was demonstrated (-31{\%} ± 51{\%} vs. -47{\%} ± 46{\%}; P = 0.38). Patients with greater than a 52{\%} decline in SUVlean max tended toward longer survival (P = 0.09) than those with lesser declines. The 12-wk overall response rate to radioimmunotherapy based on IWC was 42{\%} (14/33); complete response rate was 15{\%} (5/33). Eleven of 12 patients with progression at 12 wk had new disease sites, and in 4 patients, new disease sites were the only sites of progression. Of 108 lesions evaluated at 12 and 24 wk after radioimmunotherapy, 49 resolved at 12 wk and remained resolved at 24 wk, 17 gradually declined in SUV over 24 wk, and 37 initially decreased at 12 wk but increased at 24 wk. PET showed disease progression at 24 wk in 10 of 13 patients; 7 patients had new lesions and 1 was reclassified from partial response to complete response. Conclusion: In non-Hodgkin's lymphoma, 18F-FDG uptake in tumors typically drops significantly after radioimmunotherapy. A continued decline in tumor SUV lean max between 12 and 24 wk without additional therapy can occur, suggesting a need for delayed-response assessment. In patients who progress after radioimmunotherapy, new sites of disease commonly develop, rather than recurrence or progression at previous disease sites. Large declines in 18F-FDG uptake tend to be seen in those with the longest progression-free survival.",
keywords = "I- tositumomab, F-FDG PET, Y-ibritumomab tiuxetan, Bexxar, Lymphoma, Radioimmunotherapy, Zevalin",
author = "Jacene, {Heather A.} and Ross Filice and Wayne Kasecamp and Wahl, {Richard L.}",
year = "2009",
month = "1",
day = "1",
doi = "10.2967/jnumed.108.055376",
language = "English (US)",
volume = "50",
pages = "8--17",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "1",

}

TY - JOUR

T1 - 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy

AU - Jacene, Heather A.

AU - Filice, Ross

AU - Kasecamp, Wayne

AU - Wahl, Richard L.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - We retrospectively evaluated 18F-FDG PET/CT for monitoring the response of non-Hodgkin's lymphoma to radioimmunotherapy. Methods: A total of 33 clinical patients received 131I-tositumomab (n = 23) or 90Y-ibritumomab tiuxetan (n = 10) and underwent 18F-FDG PET/CT scans before radioimmunotherapy and at 12 wk after radioimmunotherapy. A third scan was performed on 13 patients at 24 wk after radioimmunotherapy, 12 of whom did not receive interval therapy. Tumor metabolic activity was assessed before and after radioimmunotherapy visually and quantitatively by lean maximum standardized uptake value (SUVlean max). Response was assessed by the International Workshop Criteria (IWC) and Revised IWC, which includes 18F-FDG PET (IWC-PET). Results: Mean SUVlean max decreased from baseline in 244 target lesions 12 wk after radioimmunotherapy (from 6.51 ± 4.05 to 3.94 ± 4.41; P <0.01), regardless of response at 12 wk after radioimmunotherapy (P ≤ 0.02). After radioimmunotherapy, SUV lean max was lower for responders than for nonresponders (P ≤ 0.01). Median percentage change in SUVlean max of target lesions per patient was -51% (-95% to 97%). No significant difference in decline in SUV lean max between patients who received 131I-tositumomab and those who received 90Y-ibritumomab tiuxetan was demonstrated (-31% ± 51% vs. -47% ± 46%; P = 0.38). Patients with greater than a 52% decline in SUVlean max tended toward longer survival (P = 0.09) than those with lesser declines. The 12-wk overall response rate to radioimmunotherapy based on IWC was 42% (14/33); complete response rate was 15% (5/33). Eleven of 12 patients with progression at 12 wk had new disease sites, and in 4 patients, new disease sites were the only sites of progression. Of 108 lesions evaluated at 12 and 24 wk after radioimmunotherapy, 49 resolved at 12 wk and remained resolved at 24 wk, 17 gradually declined in SUV over 24 wk, and 37 initially decreased at 12 wk but increased at 24 wk. PET showed disease progression at 24 wk in 10 of 13 patients; 7 patients had new lesions and 1 was reclassified from partial response to complete response. Conclusion: In non-Hodgkin's lymphoma, 18F-FDG uptake in tumors typically drops significantly after radioimmunotherapy. A continued decline in tumor SUV lean max between 12 and 24 wk without additional therapy can occur, suggesting a need for delayed-response assessment. In patients who progress after radioimmunotherapy, new sites of disease commonly develop, rather than recurrence or progression at previous disease sites. Large declines in 18F-FDG uptake tend to be seen in those with the longest progression-free survival.

AB - We retrospectively evaluated 18F-FDG PET/CT for monitoring the response of non-Hodgkin's lymphoma to radioimmunotherapy. Methods: A total of 33 clinical patients received 131I-tositumomab (n = 23) or 90Y-ibritumomab tiuxetan (n = 10) and underwent 18F-FDG PET/CT scans before radioimmunotherapy and at 12 wk after radioimmunotherapy. A third scan was performed on 13 patients at 24 wk after radioimmunotherapy, 12 of whom did not receive interval therapy. Tumor metabolic activity was assessed before and after radioimmunotherapy visually and quantitatively by lean maximum standardized uptake value (SUVlean max). Response was assessed by the International Workshop Criteria (IWC) and Revised IWC, which includes 18F-FDG PET (IWC-PET). Results: Mean SUVlean max decreased from baseline in 244 target lesions 12 wk after radioimmunotherapy (from 6.51 ± 4.05 to 3.94 ± 4.41; P <0.01), regardless of response at 12 wk after radioimmunotherapy (P ≤ 0.02). After radioimmunotherapy, SUV lean max was lower for responders than for nonresponders (P ≤ 0.01). Median percentage change in SUVlean max of target lesions per patient was -51% (-95% to 97%). No significant difference in decline in SUV lean max between patients who received 131I-tositumomab and those who received 90Y-ibritumomab tiuxetan was demonstrated (-31% ± 51% vs. -47% ± 46%; P = 0.38). Patients with greater than a 52% decline in SUVlean max tended toward longer survival (P = 0.09) than those with lesser declines. The 12-wk overall response rate to radioimmunotherapy based on IWC was 42% (14/33); complete response rate was 15% (5/33). Eleven of 12 patients with progression at 12 wk had new disease sites, and in 4 patients, new disease sites were the only sites of progression. Of 108 lesions evaluated at 12 and 24 wk after radioimmunotherapy, 49 resolved at 12 wk and remained resolved at 24 wk, 17 gradually declined in SUV over 24 wk, and 37 initially decreased at 12 wk but increased at 24 wk. PET showed disease progression at 24 wk in 10 of 13 patients; 7 patients had new lesions and 1 was reclassified from partial response to complete response. Conclusion: In non-Hodgkin's lymphoma, 18F-FDG uptake in tumors typically drops significantly after radioimmunotherapy. A continued decline in tumor SUV lean max between 12 and 24 wk without additional therapy can occur, suggesting a need for delayed-response assessment. In patients who progress after radioimmunotherapy, new sites of disease commonly develop, rather than recurrence or progression at previous disease sites. Large declines in 18F-FDG uptake tend to be seen in those with the longest progression-free survival.

KW - I- tositumomab

KW - F-FDG PET

KW - Y-ibritumomab tiuxetan

KW - Bexxar

KW - Lymphoma

KW - Radioimmunotherapy

KW - Zevalin

UR - http://www.scopus.com/inward/record.url?scp=58249110399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58249110399&partnerID=8YFLogxK

U2 - 10.2967/jnumed.108.055376

DO - 10.2967/jnumed.108.055376

M3 - Article

VL - 50

SP - 8

EP - 17

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -